Methods for treating lupus nephritis using fcrn antagonists
Assigneeargenx BV
InventorsTim Van Hauwermeiren, Peter Verheesen, Magdalena Sips
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of lupus nephritis and for use in the manufacture of a medicament for the treatment of lupus nephritis are also provided herein.
Claims42
A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject an effective amount of a human neonatal Fc receptor (FcRn) antagonist, wherein the FcRn antagonist comprises or consists of a variant Fc region or FcRn binding fragment thereof.
2-5. (canceled)
(canceled)
(canceled)
12-13. (canceled)
17-22. (canceled)
25-37. (canceled)
A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject an effective amount of an FcRn antagonist within 60 days of the subject receiving an induction therapy for lupus nephritis.
42-43. (canceled)
(canceled)
51-55. (canceled)
57-58. (canceled)
60-61. (canceled)
64-65. (canceled)
(canceled)
69-71. (canceled)
73-89. (canceled)
Dependencies are inferred from the claim text.